NASDAQ · NRBO
Healthcare · Biotechnology
$2.36
Up+$0.00 (+0.00%)
Updated Sep 18, 2026, 2:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NRBO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning NRBO.
NRBO research
Company profile and research snapshot.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 8, 2024 | Maxim Group | Buy | — |
| Dec 7, 2022 | Ladenburg Thalmann | Buy | — |
| Feb 1, 2021 | HC Wainwright & Co. | Buy | — |
| Jun 15, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Zacks Investment Research · Sep 29, 2023
Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals are part of the Zacks top Analyst Blog.
Zacks Investment Research · Sep 29, 2023
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
Zacks Investment Research · Sep 28, 2023
We pick three medical stocks - MOH, RDY and NRBO - that have gained more than 5% in the past three months amid market volatility.
Zacks Investment Research · Jun 6, 2023
NeuroBo Pharmaceuticals, Inc. (NRBO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NRBO.
No results
No recent SID articles mention NRBO.
